Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 in Combination With Chemotherapy in Subjects With Advanced Pancreatic Cancer
NCT07692750Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of arcotatug tavatecan in pancreatic cancer (PC), sponsored by Zhejiang Cancer Hospital. Started Apr 2025; status: recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07692750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692750.